CLAIMS

[Claim 1]

An agent for suppressing transient lower esophageal sphincter relaxation, comprising 4-[({6-[isobutyl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}oxy)methyl]-3-methyl benzoic acid, a salt thereof or a prodrug thereof as an active ingredient.

[Claim 2]

The agent according to claim 1, which reduces the frequency of transient lower esophageal sphincter relaxation.

[Claim 3]

An agent for suppressing the reflux of gastric acid and/or gastric contents, comprising 4-[({6-[isobutyl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}oxy)methyl]-3-methyl benzoic acid, a salt thereof or a prodrug thereof as an active ingredient.

[Claim 4]

An agent for preventing or relapse-preventing gastroesophageal reflux disease, comprising 4-[({6-[isobutyl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}oxy)methyl]-3-methyl benzoic acid, a salt thereof or a prodrug thereof as an active ingredient.

[Claim 5]

An agent comprising 4-[({6-[isobutyl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}oxy)methyl]-3-methyl benzoic acid, a salt thereof or a prodrug thereof as an active ingredient, for use in treatment of gastroesophageal reflux disease.

[Claim 6]

The agent according to claim 5, wherein the gastroesophageal reflux disease is non-erosive.

[Claim 7]

The agent according to claim 5 or 6, wherein the symptoms of the gastroesophageal reflux disease are heartburn and/or acid reflux.

[Claim 8]

The agent according to any one of claims 5 to 7, wherein the gastroesophageal reflux disease is resistant to a proton pump inhibitor.

[Claim 9]

The agent according to claim 8, wherein the proton pump inhibitor is a medicine selected from omeprazole, esomeprazole, pantoprazole, rabeprazole, tenatoprazole, ilaprazole and lansoprazole.

CLAIMS

[Claim 1]

The use of an agent comprising 4-[({6-[isobutyl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}oxy)methyl]-3-methyl benzoic acid, a salt thereof or a prodrug thereof in the manufacture of a medicament for suppressing transient lower esophageal sphincter relaxation.

[Claim 2]

The use according to claim 1, which reduces the frequency of transient lower esophageal sphincter relaxation.

[Claim 3]

The use of an agent comprising 4-[({6-[isobutyl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}oxy)methyl]-3-methyl benzoic acid, a salt thereof or a prodrug thereof in the manufacture of a medicament for suppressing the reflux of gastric acid and/or gastric contents.

[Claim 4]

The use of an agent comprising 4-[({6-[isobutyl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}oxy)methyl]-3-methyl benzoic acid, a salt thereof or a prodrug thereof in the manufacture of a medicament for preventing or relapse-preventing gastroesophageal reflux disease.

[Claim 5]

The use of an agent comprising 4-[({6-[isobutyl(1,3-thiazol-2-ylsulfonyl)amino]-2,3-dihydro-1H-inden-5-yl}oxy)methyl]-3-methyl benzoic acid, a salt thereof or a prodrug thereof in the manufacture of a medicament for the treatment of gastroesophageal reflux disease;

wherein the gastroesophageal reflux disease is resistant to a proton pump inhibitor.

[Claim 6]

The use according to claim 5, wherein the gastroesophageal reflux disease is non-erosive.

[Claim 7]

The use according to claim 5 or 6, wherein the symptoms of the gastroesophageal reflux disease are heartburn and/or acid reflux.

[Claim 8]

The use according to claim 5, wherein the proton pump inhibitor is a medicine selected from omeprazole, esomeprazole, pantoprazole, rabeprazole, tenatoprazole, ilaprazole and lansoprazole.